glp 1 neurological effects GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives GLP-1 for Weight Loss and
Description
Lifestyle as part of GLP-1 weight-loss treatment The World Health Organization (WHO) released new guidelines on the use of GLP-1 drugs in treating obesity in December 2025, emphasizing the importance of lifestyle changes alongside GLP-1 treatment
Funding The author(s) declare that no financial support was received for the research and/or publication of this article
That means training with purpose
After a week of [ 68 Ga]DOTATOC PET/CT scans, [ 18 F]FB(ePEG12)12-exendin-4 PET/CT imaging was performed in two phases, 30 min (early-phase) and 120 min (delayed-phase) postinjection, of the [ 18 F]FB(ePEG12)12-exendin-4 tail vein (0.148 MBq/mouse) under 2.0% isoflurane anesthesia using a Triumph LabPET12/SPECT4/CT
Ive now lost another 10 pounds and feel in control again
Trial results vary by drug, dose, baseline weight, adherence, side-effect tolerance, and whether patients can stay on treatment
